PLx Pharma, which is commercializing a delayed-release aspirin based on its proprietary lipid coating, withdrew its plans for an initial public offering on Monday. It had filed to raise $68 million by offering 3.8 million shares at a price range of $17 to $19.
The Houston, TX-based company was founded in 2002 and had planned to list on the Nasdaq under the symbol PLXP. Raymond James and Maxim Group LLC were set to be the joint book runners on the deal.
Blogger Comment
Facebook Comment